{"symbol":"REGN","fiscalQuarter":"Q2-2025","reportDate":"2025-08-01","reportTime":"BMO","status":"reported","company":{"name":"Regeneron Pharmaceuticals, Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/REGN/earnings/Q2-2025","postBrief":{"headline":"Regeneron Pharmaceuticals Beats on EPS, Stock Up 2.46%","keyNumbers":[{"metric":"EPS","actual":"$12.89","expected":"N/A","surprise":"+94.45%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["Management highlighted strong performance in key product areas.","They emphasized ongoing commitment to innovation and research."],"summary":"Overall, management expressed confidence in their current product pipeline. They acknowledged market challenges but remain focused on growth."},"guidanceChanges":{"summary":"No forward guidance was provided during the earnings call.","changes":[]},"whatItMeans":"Regeneron's strong EPS performance, significantly exceeding expectations, led to a positive stock reaction, with shares rising by 2.46%. The company did not provide revenue figures or future guidance, leaving some uncertainty. However, management's optimistic tone suggests they are confident in their ongoing projects and market position.","metaDescription":"Regeneron Pharmaceuticals (REGN) Q2 2025 earnings: EPS beat by 94.45%. Stock up 2.46%. Full breakdown."}}